A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

被引：3
|
作者：
Navada, Shyamala C. [1 ]
Garcia-Manero, Guillermo [2 ]
Wilhelm, Francois [3 ]
Hearn, Katherine [2 ]
Odchimar-Reissig, Rosalie [1 ]
Demakos, Erin P. [1 ]
Alvarado, Yesid [2 ]
Daver, Naval [2 ]
DiNardo, Courtney D. [2 ]
Konopleva, Marina [2 ]
Borthakur, Gautam [2 ]
Azarnia, Nozar
Silverman, Lewis R. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Onconova Therapeut Inc, Newtown, PA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3252.3252
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [2] A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
    Navada, Shyamala C.
    Silverman, Lewis R.
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney
    Konopleva, Marina
    Borthakur, Gautam
    Pemmaraju, Naveen
    Kadia, Tapan
    Fenaux, Pierre
    Fruchtman, Steve
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2015, 126 (23)
  • [3] RESULTS FROM PHASE I/II STUDY OF THE COMBINATION OF ORAL RIGOSERTIB AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Fenaux, P.
    Fruchtman, S.
    Zbyszewski, P.
    Silverman, L.
    [J]. HAEMATOLOGICA, 2016, 101 : 74 - 74
  • [4] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    [J]. BLOOD, 2012, 120 (21)
  • [5] Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    OdchimarReissig, Rosalie
    Pemmaraju, Naveen
    Alvarado, Yesid
    Ohanian, Maro N.
    John, Rosmy B.
    Demakos, Erin P.
    Zbyszewski, Patrick S.
    Maniar, Manoj
    Woodman, Richard C.
    Fruchtman, Steven M.
    Silverman, Lewis R.
    [J]. LEUKEMIA RESEARCH, 2020, 94
  • [6] Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Fenaux, Pierre
    Petrone, Michael E.
    Zbyszewski, Patrick Simon
    Fruchtman, Steven M.
    Silverman, Lewis R.
    [J]. BLOOD, 2016, 128 (22)
  • [7] ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAIVE AND RELAPSED/REFRACTORY PATIENTS
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Fenaux, P.
    Petrone, M.
    Zbyszewski, P.
    Fruchtman, S.
    Silverman, L.
    [J]. HAEMATOLOGICA, 2017, 102 : 183 - 184
  • [8] COMBINATION OF ORAL RIGOSERTIB AND INJECTABLE AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Fenaux, P.
    Petrone, M.
    Zbyszewski, P.
    Fruchtman, S.
    Silverman, L.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S30 - S30
  • [9] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2014, 124 (21)
  • [10] A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium
    Silverman, L. R.
    Verma, A.
    Odchimar-Reissig, R.
    Cozza, A.
    Najfeld, V.
    Licht, J. D.
    Zwiebel, J. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345